As Senior Vice President, Major Markets, Catherine Owen is responsible for BMS business in the largest global markets including Europe, Japan and Canada. In addition, she is responsible for ~$12BN (35%) of BMS total global sales, spanning therapeutic areas including Oncology, Hematology, CART, Cardiovascular, and Immunology, with many recognizable brands including OPDIVO, REVLIMID, ELIQUIS, and ORENCIA. She has 8 company General Managers/Presidents reporting to her, responsible for over 6000 employees. Owen has led the complex integration of her BMS businesses with Celgene over the past 2 years, as well as multiple new product launches in multiple sclerosis, multiple myeloma, lung cancer, renal cancer and ulcerative colitis. Owen has led the integration & transition during the global pandemic, responding rapidly to changes in the commercial operating model, commercialization, supply chain and legal entity rationalization. She has championed the development of a new focus on global end of lifecycle management, including the creation of a new global franchise responsible for Established Brands, which she now leads. Owen is the global sponsor for the BMS General Manager development program, as well as representing BMS in EFPIA on the Patient Access Committee, a board member for the Pennsylvania Conference for Women, as well as on the board of Robert Wood Johnson Hospital System, the largest hospital system in New Jersey. Previously Owen was a senior executive at Johnson & Johnson (J&J). In her last role, she was President, Immunology, USA at Janssen Pharmaceuticals, responsible for leading the largest single business unit within J&J. The business included brands such as STELARA, REMICADE, SIMPONI and TREMFYA, leading over 1000 employees, and serving patients within the areas of dermatology, gastroenterology, and rheumatology. Previously, Owen was President, Infectious Diseases and Vaccines, where she led the U.S. commercial business in making a difference in the lives of people living with HIV, RSV and Ebola. Owen began her Johnson & Johnson career as a London-based sales representative. During her more than 25 years with J&J, she held leadership roles in Pharmaceuticals, Medical Devices and Corporate Innovation in the U.K., the U.S., Europe and global organizations. With a passion for digital connectivity, Owen established the first North America Pharmaceuticals Digital Governance Board and digital champions’ team at Janssen and served as Digital Governance Lead for North America. She also served as the first leader of the Janssen North America Culture Team, and in her role as Diversity & Inclusion lead for North America, Owen built the first Employee Resource Group Council. Owen is passionate about developing people, improving the lives of patients suffering from serious disease, and serves as a career mentor for many. In recognition of her efforts, she received the M&M Hall of Femme award in 2020, the Healthcare Businesswomen’s Association Luminary award in 2018 and represented J&J at Forbes ‘NexGen’ most powerful woman in Pharma. Additionally, Owen is an independent director on the Board of Directors at Optinose LLC in NJ. Owen has an Honors degree in Pharmacy from the University of Manchester and a post-graduate degree in Marketing from the University of London. She is a member of the Royal Pharmaceutical Society of Great Britain and is an Associate of the Chartered Institute of Marketing. She lives in Pennington, NJ with her husband and two teenage daughters.